Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2025-12-26 @ 2:32 AM
Study NCT ID:
NCT04240002
Status:
TERMINATED
Last Update Posted:
2025-05-28
First Post:
2020-01-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-03-17
Completion Date Type:
ACTUAL
First Submit Date:
2020-01-21
First Submit QC Date:
None
Study First Post Date:
2020-01-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-26
Last Update Post Date:
2025-05-28
Last Update Post Date Type:
ACTUAL